New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
08:05 EDTPCYCPharmacyclics reports Q1 EPS 23c, consensus 17c
Reports Q1 adjusted EPS 40c, compared to 40c a year ago. Reports Q1 revenue $119.4M, consensus $105.38M
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
08:14 EDTPCYCPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
October 17, 2014
08:57 EDTPCYCPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTPCYCPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:34 EDTPCYCPharmacyclics management to meet with JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use